Amir is an executive partner in our Boston office and focuses on portfolio company executive roles as well as investing in healthcare companies. He joined Polaris in 2002 and also serves as a managing partner of Polaris Funds VI – IX.
Amir currently represents Polaris as a Director of AgBiome, CAMP4 Therapeutics, Dewpoint Therapeutics, Kojin Therapeutics, Metacrine Therapeutics, Morphic Therapeutic (NASDAQ: MORF), Primmune Therapeutics, and Scholar Rock (NASDAQ: SRRK).
Additionally, Amir has served as a director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Fate Therapeutics (NASDAQ: FATE), Freenome, Living Proof (Unilever), Promedior Pharmaceuticals (Roche), Receptos (Celgene), Selecta Biosciences (NASDAQ: SELB), Sun Catalytix (Lockheed Martin), Syros Pharmaceuticals (NASDAQ: SYRS), and TARIS Biomedical (J&J). He was also CEO of Polaris portfolio companies Dewpoint, Jnana, Living Proof, Olivo Labs, and Sun Catalytix.
Amir also serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.
He has been named to the Forbes Midas List of “Top 100 Venture Capitalists” (2016).
Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.